Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the low priced stocks to buy with high upside potential. On December 12, Bank of America raised the firm’s price target on Ocular Therapeutix to $21 ...

Oct 10 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to ...

Drugmaker Bristol-Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing ...

The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a ...

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further ...

Bristol Myers Squibb has agreed to buy privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash in a deal that bolsters the drugmaker's cell-therapy portfolio. Bristol Myers ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ocular Therapeutix ( (OCUL)) just ...

IoCDB Share project repository, a CTI platform that collects data from VirusTotal, AlienVault OTX, PolySwarm and AbuseIPDB APIs for hashes, domains and IPs. AegisFlow is a threat-aware CI/CD pipeline ...

Dr. Raff to lead Clinical and Regulatory Operations to guide advancement of OTX-201, a potential best-in-class program for B cell-driven autoimmune diseases, toward clinical development in 1H’26 ...

College Football CFB - Texas Longhorns vs. Ohio State Buckeyes - 08/30/2025 Ohio State Buckeyes Texas Longhorns BIG NOON KICKOFF ...